dea

ENDEAVOR IV Clinical Trial Meets Primary Endpoint

MINNEAPOLIS--(BUSINESS WIRE)--Jul 2, 2007 - Medtronic, Inc.,(NYSE:MDT) today announced that a review of data from the ENDEAVORIV Clinical Trial indicates that the trial has met its primary,non-inferiority endpoint. The ENDEAVOR IV Clinical Trial is a randomized, single-blindtrial evaluating the safety and efficacy of the Endeavor(TM) DrugEluting Coronary Stent as compared to the TAXUS Pac...

Dean: President Bush Has Turned His Back on the American People

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- DemocraticNational Committee Chairman Howard Dean issued the followingstatement today after President Bush once again put politics aheadof science by vetoing the Stem Cell Research Enhancement Act of2007. The legislation, providing federal funding for life-savingembryonic stem cell research, has the overwhelming support of theAm...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

Medtronic Announces Positive Nine-Month Results for Endeavor Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor IanMeredith, M.D., Monash Medical Centre, Melbourne, Australia, onTuesday presented positive nine-month results from the MedtronicRESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain,with data showing a low number of adverse cardiac events and noprotocol-defined stent thrombosis. The next-generation Medtronic(NYSE:MDT...

Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Medtronic(NYSE:MDT) today presented new long-term data from the ENDEAVORclinical trial program reinforcing the existing safety and efficacyprofile of the Endeavor(R) drug-eluting coronary stent system.Four-year results from the 100-patient first-in-man ENDEAVOR Itrial and three-year results from the nearly 1,200 patient ENDEAVORII trial demo...

Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies

-- Large multi-year, multi-hospital retrospective database analysisdemonstrates RDS treatment with Curosurf(R) (poractant alfa)Intratracheal Suspension provides significantly improved neonatalsurvival -- NAPA, Calif. and PARMA, Italy, May 07, 2007 /PRNewswire/ -- Datapresented today at the Pediatric Academic Societies' Annual Meetingdemonstrate that premature infants with neonatal Respira...

New Research Results Show That Investigational Drug Phenoxodiol Targets Cancer Protein, Causing Cancer Cell Death

Worldwide pivotal phase III study in women with recurrent ovariancancer underway SYDNEY, Australia and WASHINGTON, May 01, 2007/PRNewswire-FirstCall/ -- A new study further supports the uniquemechanism of action of phenoxodiol, an investigational drug beingstudied for the treatment of ovarian cancer. The drug appears towork by targeting a certain tumor-specific protein, which triggersa s...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stent's Positive Clinical Profile

MINNEAPOLIS--(BUSINESS WIRE)--Mar 26, 2007 - Two-year results fromthe Medtronic (MDT:NYSE) ENDEAVOR III trial confirm the positiveclinical profile of the Endeavor(R) drug-eluting coronary stent andbring to nearly 1,300 the number of Endeavor patients who have atleast two years of follow-up. Significantly, among those 1,300Endeavor patients, there have been no reported cases of late stentthr...